

## **IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023**

**POTOMAC, MARYLAND / ACCESSWIRE / April 18, 2023 / IGC Pharma, Inc.** (NYSE American: IGC) today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023, at 4:30 PM (Local Time -PDT). Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principal Financial Officer, will be hosting the presentation and answering questions at the conclusion.

To access the live presentation, please use the following information:

### **Planet MicroCap Showcase: VEGAS 2023**

Date: Wednesday, April 26, 2023

Time: 7:30 PM Eastern Time (4:30 PM Pacific Time)

Webcast: <https://www.webcaster4.com/Webcast/Page/2963/48000>

If you would like to book 1x1 investor meetings with IGC Pharma and to attend the Planet MicroCap Showcase: VEGAS 2023, please make sure you are registered here:

<https://planetmicrocapshowcase.com/signup>

1x1 meetings will be scheduled and conducted in person at the conference venue in LAS VEGAS.

The Planet MicroCap Showcase: VEGAS 2023 website is available here:

<https://planetmicrocapshowcase.com/>

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda":

<https://planetmicrocapshowcase.com/agenda>

---

### **News Compliments of [Accesswire](#)**

#### **About IGC Pharma, Inc.**

IGC Pharma (dba IGC) develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps ("dysmenorrhea"), premenstrual syndrome ("PMS") and chronic pain. IGC has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol ("THC") based formulation that is currently in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's ([clinicaltrials.gov](https://clinicaltrials.gov), NCT05543681). IGC also markets a wellness brand, Holief™, that targets women experiencing premenstrual syndrome and menstrual cramps. For more information visit <https://igcinc.us/>

#### **About Planet MicroCap**

Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space.

If you would like to attend the Planet MicroCap Showcase, please register here:  
<https://planetmicrocapshowcase.com/signup>

**Contact:**

IMS Investor Relations

Walter Frank

[igc@imsinvestorrelations.com](mailto:igc@imsinvestorrelations.com)

(203) 972-9200

**Source:** IGC Pharma, Inc. via SNN Network